Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...
Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial ...
Investor's Business Daily on MSN28m
AbbVie Has A New Cash Cow As Humira Bows To Skyrizi In Third-Quarter BeatAbbVie easily beat third-quarter expectations and raised its earnings outlook for the year. AbbVie stock rose Wednesday.
AnaptysBio (ANAB) stock plunged after Eli Lilly's (LLY) decision to discontinue arthritis candidate peresolimab from its pipeline. Read more here.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
Donald Trump and Robert F. Kennedy Jr.’s recent vow to tackle public health issues together signals a shift in Republican priorities.
Telix Pharmaceuticals leverages a novel theranostic approach, offering a unique risk-reward model in the challenging biotech ...
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 819% — a market-crushing outperformance compared to 170% for the S&P 500.* They just ...
Typically, if it’s a planned handover, the CEO starts in six months to a year of being announced. Investors and employees ...
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the ...
GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...
Breast cancer is on the rise in Virginia, as well as the costs associated with treatment. Vance defends MSG rally; Dodgers take 3-0 lead over Yankees ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback